PureTech Health (LON:PRTC) Shares Down 15.2% - Time to Sell?

Shares of PureTech Health plc (LON:PRTC - Get Free Report) fell 15.2% during trading on Tuesday . The company traded as low as GBX 117.20 ($1.53) and last traded at GBX 117.20 ($1.53). 42,764,352 shares changed hands during mid-day trading, an increase of 2,645% from the average session volume of 1,557,904 shares. The stock had previously closed at GBX 138.20 ($1.81).

Analyst Upgrades and Downgrades

Separately, Jefferies Financial Group reaffirmed a "buy" rating and set a GBX 455 ($5.96) price objective on shares of PureTech Health in a research note on Monday, December 16th.

PureTech Health Price Performance

The business has a 50 day simple moving average of GBX 135.24 and a two-hundred day simple moving average of GBX 148.08. The firm has a market capitalization of £354.45 million, a P/E ratio of -4.84 and a beta of 1.02. The company has a debt-to-equity ratio of 45.82, a quick ratio of 2.51 and a current ratio of 3.68.

PureTech Health Company Profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.